(Adnkronos) – “Industry is not interested. We did a study with a combination of acetylcarnitine and riluzole and we saw an increase in lifespan. But we should do a larger one and perhaps start from the beginning of the disease. But it is impossible to find financial resources for such a study. With a modest sum like one billion euros per year for the European Commission we could have 20 groups in Europe studying remedies for rare diseases”
#ALS #Garattini #Mario #Negri #Institute #therapy #call #ALS #today #disease
ALS, Garattini (Mario Negri Institute), “far from therapy because not everything we call ALS today is the same disease”
